As previously reported, Exane BNP Paribas analyst Nate Crossett upgraded Medical Properties Trust to Outperform from Neutral with an unchanged price target of $6 after the company recently reported Q4 results and gave an update on its capital allocation strategy. The firm is positive on the shares given the “numerous potential positive catalysts” it sees, including possible asset sales and secured debt financing transactions, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MPW:
- Medical Properties Stock (NYSE:MPW): Deleveraging Continues at Attractive Terms
- Options Volatility and Implied Earnings Moves Today, February 21, 2024
- Medical Properties Trust price target lowered to $5 from $8 at RBC Capital
- Medical Properties Trust (MPW) Q4 Earnings Cheat Sheet
- Medical Properties Trust initiated with a Sell at Deutsche Bank
